NasdaqGS:MRVILife Sciences
Maravai LifeSciences Holdings (MRVI) Posts US$130.8m TTM Loss Challenging Margin Recovery Narratives
Maravai LifeSciences Holdings (MRVI) has wrapped up FY 2025 with fourth quarter revenue of US$49.9 million and a basic EPS loss of US$0.25, set against a trailing twelve month loss of US$0.91 per share on revenue of US$185.7 million. Over recent quarters the company has seen revenue move from US$56.4 million in Q4 2024 to US$41.6 million in Q3 2025 and then to US$49.9 million in Q4 2025. Quarterly basic EPS has ranged from a loss of US$0.19 in Q4 2024 to losses between US$0.18 and US$0.27...